search
Back to results

Kaitoh Atherectomy FIH

Primary Purpose

Peripheral Arterial Disease

Status
Recruiting
Phase
Not Applicable
Locations
New Zealand
Study Type
Interventional
Intervention
Kaitoh Atherectomy System
Sponsored by
Terumo Medical Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥18 years old Rutherford Classification: 3-5 in target limb; a. Rutherford Classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (no more than two Rutherford Class 3 subjects may be enrolled into the study). Able and willing to provide informed consent, and comply with follow-up visits at both 30 days and 180 days (6 months) Able to comply with antiplatelet therapy as required Exclusion Criteria: Females who are pregnant or lactating Pre-existing illness with life expectancy <1 year Known or suspected systemic infection Endovascular or surgical procedure performed on the target lesion within 3 months of the index procedure Subjects scheduled to undergo a planned major amputation of the lower limb above the ankle on the target limb Allergic to any of the components of the atherectomy device system Intraprocedural complications prior to use of the investigational device

Sites / Locations

  • Auckland HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Kaitoh Atherectomy System

Arm Description

Eligible participants will undergo atherectomy using the Kaitoh Atherectomy System.

Outcomes

Primary Outcome Measures

Freedom from major adverse events (MAEs)
Primary Safety
Technical success as confirmed by angiography core lab
Effectiveness

Secondary Outcome Measures

Full Information

First Posted
March 20, 2023
Last Updated
August 9, 2023
Sponsor
Terumo Medical Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT05873452
Brief Title
Kaitoh Atherectomy FIH
Official Title
Kaitoh Atherectomy System: Peripheral Artery Revascularization of Stenotic/Restenotic Disease Using the Atherectomy System in the Peripheral Arteries
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 7, 2023 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Terumo Medical Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, single-center and single-arm clinical study to assess the initial safety and effectiveness of the Kaitoh Atherectomy System for the treatment of de novo and/or restenotic lesion(s) in the peripheral arteries.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Kaitoh Atherectomy System
Arm Type
Experimental
Arm Description
Eligible participants will undergo atherectomy using the Kaitoh Atherectomy System.
Intervention Type
Device
Intervention Name(s)
Kaitoh Atherectomy System
Intervention Description
The Kaitoh Atherectomy System is a handheld device which initiates mechanical rotation of the blade to debulk atherosclerotic lesions.
Primary Outcome Measure Information:
Title
Freedom from major adverse events (MAEs)
Description
Primary Safety
Time Frame
30 days post-procedure
Title
Technical success as confirmed by angiography core lab
Description
Effectiveness
Time Frame
through completion of interventional 1 day procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old Rutherford Classification: 3-5 in target limb; a. Rutherford Classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (no more than two Rutherford Class 3 subjects may be enrolled into the study). Able and willing to provide informed consent, and comply with follow-up visits at both 30 days and 180 days (6 months) Able to comply with antiplatelet therapy as required Exclusion Criteria: Females who are pregnant or lactating Pre-existing illness with life expectancy <1 year Known or suspected systemic infection Endovascular or surgical procedure performed on the target lesion within 3 months of the index procedure Subjects scheduled to undergo a planned major amputation of the lower limb above the ankle on the target limb Allergic to any of the components of the atherectomy device system Intraprocedural complications prior to use of the investigational device
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Stevens
Phone
908-208-4238
Email
jennifer.stevens@terumomedical.com
First Name & Middle Initial & Last Name or Official Title & Degree
Charis Sugden
Phone
908-514-6154
Email
charis.sugden@terumomedical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Holden
Organizational Affiliation
Auckland City Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Auckland Hospital
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cynthia Corne

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Not sharing IPD

Learn more about this trial

Kaitoh Atherectomy FIH

We'll reach out to this number within 24 hrs